- Home
- CHEK vs TOVX Comparison
CHEK vs TOVX Comparison
Compare CHEK & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- TOVX
- Stock Information
- Founded
- CHEK 2004
- TOVX 2001
- Country
- CHEK Israel
- TOVX United States
- Employees
- CHEK N/A
- TOVX N/A
- Industry
- CHEK Medical Electronics
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CHEK Health Care
- TOVX Health Care
- Exchange
- CHEK Nasdaq
- TOVX Nasdaq
- Market Cap
- CHEK 3.9M
- TOVX 3.8M
- IPO Year
- CHEK 2015
- TOVX 2006
- Fundamental
- Price
- CHEK $1.94
- TOVX $0.62
- Analyst Decision
- CHEK
- TOVX Hold
- Analyst Count
- CHEK 0
- TOVX 1
- Target Price
- CHEK N/A
- TOVX N/A
- AVG Volume (30 Days)
- CHEK 474.1K
- TOVX 1.4M
- Earning Date
- CHEK 11-14-2025
- TOVX 11-11-2025
- Dividend Yield
- CHEK N/A
- TOVX N/A
- EPS Growth
- CHEK N/A
- TOVX N/A
- EPS
- CHEK N/A
- TOVX N/A
- Revenue
- CHEK N/A
- TOVX N/A
- Revenue This Year
- CHEK N/A
- TOVX N/A
- Revenue Next Year
- CHEK N/A
- TOVX N/A
- P/E Ratio
- CHEK N/A
- TOVX N/A
- Revenue Growth
- CHEK N/A
- TOVX N/A
- 52 Week Low
- CHEK $0.56
- TOVX $0.37
- 52 Week High
- CHEK $3.13
- TOVX $2.64
- Technical
- Relative Strength Index (RSI)
- CHEK 52.35
- TOVX 75.27
- Support Level
- CHEK $1.84
- TOVX $0.43
- Resistance Level
- CHEK $2.13
- TOVX $0.51
- Average True Range (ATR)
- CHEK 0.19
- TOVX 0.06
- MACD
- CHEK -0.09
- TOVX 0.02
- Stochastic Oscillator
- CHEK 16.67
- TOVX 64.03
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.